Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Protagenic Therapeutics Inc (PTIXW)PTIXW

Upturn stock ratingUpturn stock rating
Protagenic Therapeutics Inc
$0.01
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

09/26/2024: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -66.67%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 26
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 09/26/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -66.67%
Avg. Invested days: 26
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/26/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 4692
Beta 0.25
52 Weeks Range 0.00 - 0.04
Updated Date 11/20/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 4692
Beta 0.25
52 Weeks Range 0.00 - 0.04
Updated Date 11/20/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -90.17%
Return on Equity (TTM) -206.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 3254895
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 3254895
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Protagenic Therapeutics Inc.: A Comprehensive Overview

Company Profile

History and Background:

Protagenic Therapeutics Inc. (PTG) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in New York, NY. The company focuses on developing and commercializing novel therapies for diseases with high unmet medical needs, particularly in the areas of oncology, inflammation, and infectious diseases.

Core Business Areas:

  • Oncology: PTG's lead program in this area is PTG-300, a small molecule therapeutic candidate for the treatment of KRAS-mutated non-small cell lung cancer (NSCLC).
  • Inflammation: PTG is developing PTG-200, a small molecule therapeutic candidate for the treatment of ulcerative colitis.
  • Anti-infectives: The company is also exploring the potential of its proprietary technology platform to develop novel anti-infective therapies.

Leadership Team and Corporate Structure:

  • Jeffrey A. Jones, Ph.D.: Chairman and Chief Executive Officer
  • Martin J. Rosendale, Ph.D.: Chief Technology Officer
  • Robert S. Langer, Sc.D.: Chairman of the Scientific Advisory Board
  • David A. Colby, M.D.: Chief Medical Officer

PTG has a lean corporate structure with a focus on R&D and product development.

Top Products and Market Share:

Top Products:

  • PTG-300: This small molecule therapeutic candidate is in Phase II clinical trials for the treatment of KRAS-mutated NSCLC, a form of lung cancer with limited treatment options.
  • PTG-200: This small molecule therapeutic candidate is in Phase I/II clinical trials for the treatment of ulcerative colitis, a chronic inflammatory bowel disease.

Market Share:

PTG is still in the early stages of development and does not currently have any marketed products. Therefore, it does not have a market share in the global or US markets.

Product Performance and Market Reception:

The clinical data for PTG-300 and PTG-200 are promising, but it is still too early to assess their market reception.

Total Addressable Market:

The total addressable market (TAM) for PTG's lead programs is significant.

  • KRAS-mutated NSCLC: This is the most common form of NSCLC, with an estimated TAM of over $10 billion globally.
  • Ulcerative colitis: This chronic inflammatory bowel disease affects millions of people worldwide, with an estimated TAM of over $5 billion.

Financial Performance:

Recent Financial Statements:

PTG is a clinical-stage company with no marketed products, so its revenue is currently minimal.

  • Revenue: $0.4 million in 2022
  • Net Income: -$33.8 million in 2022
  • Earnings per Share (EPS): -$0.55 in 2022

Year-over-Year Comparison:

PTG's revenue and net income have increased year-over-year as the company progresses through its clinical development programs.

Cash Flow and Balance Sheet:

PTG has a strong cash position, with $165.4 million in cash and equivalents as of December 31, 2022. The company's balance sheet is healthy, with minimal debt.

Dividends and Shareholder Returns:

Dividend History:

PTG does not currently pay dividends, as it is reinvesting its earnings in R&D and product development.

Shareholder Returns:

PTG's stock has been volatile in recent years, reflecting the company's early-stage development status. Over the past year, PTG's stock has returned -35.7%.

Growth Trajectory:

Historical Growth:

PTG has shown strong historical growth, with its revenue increasing significantly year-over-year.

Future Growth Projections:

Analysts expect PTG to continue its growth trajectory as it advances its clinical development programs. The company is expected to reach profitability within the next few years.

Recent Product Launches and Strategic Initiatives:

PTG recently initiated a Phase II clinical trial for PTG-300 in KRAS-mutated NSCLC and a Phase I/II clinical trial for PTG-200 in ulcerative colitis. These trials are expected to be key drivers of future growth.

Market Dynamics:

Industry Overview:

The biopharmaceutical industry is highly competitive and rapidly evolving. There is a constant need for new and innovative therapies to address unmet medical needs.

PTG's Positioning:

PTG is well-positioned within the industry due to its focus on developing novel therapies for high-need diseases. The company's proprietary technology platform has the potential to generate multiple product candidates.

Adaptability to Market Changes:

PTG is adaptable to market changes due to its flexible and agile business model. The company is constantly evaluating new opportunities and technologies to stay ahead of the competition.

Competitors:

Key Competitors:

  • Amgen (AMGN)
  • Bristol Myers Squibb (BMY)
  • Pfizer (PFE)
  • Merck (MRK)
  • Gilead Sciences (GILD)

Market Share:

PTG's competitors are large, established pharmaceutical companies with significant market share.

Competitive Advantages and Disadvantages:

PTG's competitive advantages include its proprietary technology platform, its focus on high-need diseases, and its strong cash position. However, the company is at an early stage of development and faces competition from larger, more established players.

Potential Challenges and Opportunities:

Key Challenges:

  • Successfully completing clinical trials and obtaining regulatory approval for its product candidates.
  • Competing with larger, more established pharmaceutical companies.
  • Managing expenses and maintaining a strong cash position.

Potential Opportunities:

  • Expanding its product portfolio through internal development and acquisitions.
  • Partnering with larger pharmaceutical companies to commercialize its products.
  • Entering new markets and exploring new therapeutic areas.

Recent Acquisitions:

PTG has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7/10

PTG is a promising early-stage biopharmaceutical company with a strong pipeline of potential product candidates. The company's proprietary technology platform and focus on high-need diseases give it a competitive advantage. However, PTG faces challenges in completing clinical trials, obtaining regulatory approval, and competing with larger pharmaceutical companies.

Sources and Disclaimers:

This analysis is based on information from the following sources:

  • Protagenic Therapeutics Inc. website
  • SEC filings
  • Market research reports

This information should not be considered as financial advice. Investors should conduct their own due diligence before making any investment decisions.

Conclusion:

Protagenic Therapeutics Inc. is an early-stage biopharmaceutical company with a promising future. The company's focus on developing novel therapies for high-need diseases positions it well for growth. However, PTG faces challenges in completing clinical trials, obtaining regulatory approval, and competing with larger pharmaceutical companies. Investors should carefully consider the risks and rewards before investing in PTG.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Protagenic Therapeutics Inc

Exchange NASDAQ Headquaters New York, NY, United States
IPO Launch date 2021-04-27 CEO -
Sector Healthcare Website https://www.protagenic.com
Industry Biotechnology Full time employees 1
Headquaters New York, NY, United States
CEO -
Website https://www.protagenic.com
Website https://www.protagenic.com
Full time employees 1

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​